Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 26:12:651438.
doi: 10.3389/fendo.2021.651438. eCollection 2021.

Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches

Andrea Lania  1   2 , Francesco Ferraù  3   4 , Manila Rubino  5 , Roberta Modica  6 , Annamaria Colao  6 , Antongiulio Faggiano  7   8
Affiliations
Review

Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches

Andrea Lania et al. Front Endocrinol (Lausanne). .

Abstract

Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors, their treatment being challenging and requiring a multidisciplinary approach. Though the only curative treatment is surgery, up to 50% of patients are diagnosed with metastatic disease. In the last years, neoadjuvant chemo(radio)therapy has become part of the standard of care in the treatment of different cancer types. However, evidence of its efficacy and safety in NEN patients has not yet been confirmed in the literature. The aim of the present review is to perform an extensive review of the scientific evidence for neoadjuvant therapy in patients with gastroenteropancreatic and thoracic NENs.

Keywords: capecitabine; chemotherapy; everolimus; neuroendocrine tumors; peptide receptor radionuclide therapy; somatostatin (analogs and derivatives); temozolomide.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. . Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol (2017) 3:1335–42. 10.1001/jamaoncol.2017.0589 - DOI - PMC - PubMed
    1. Perysinakis I, Aggeli C, Kaltsas G, Zografos GN. Neoadjuvant Therapy for Advanced Pancreatic Neuroendocrine Tumors: An Emerging Treatment Modality? Hormones (Athens) (2016) 15(1):15–22. 10.14310/horm.2002.1636 - DOI - PubMed
    1. Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, et al. . The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas (2017) 46(6):715–31. 10.1097/MPA.0000000000000846 - DOI - PMC - PubMed
    1. Tsoli M, Spei ME, Wallin G, Kaltsas G, Daskalakis K. Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms With Survival: A Systematic Review and Meta-Analysis. Cancers (Basel) (2020) 12(8):2246. 10.3390/cancers12082246 - DOI - PMC - PubMed
    1. Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol (2020) 10:245. 10.3389/fonc.2020.00245 - DOI - PMC - PubMed